Endo Sees Strong Prospects For Hybrid Injectables Pipeline

 
• By Akriti Seth and Aidan Fry

Endo has high hope for its pipeline of 505(b)(2) hospital and critical-care drugs in the US as the group looks to return to revenue growth.

Syringes
Endo is lining up a pipeline of differentiated injectables via the US 505(b)(2) regulatory pathway • Source: Shutterstock

More from Value Added Medicines

More from Products